This study combines techniques in genetic epidemiology and molecular genetics to define and characterize inherited breast and breast/ovarian cancer predisposing syndromes. It focuses on two hereditary syndromes: (1) the Li-Fraumeni syndrome, known to be caused by mutations in the tumor suppressor gene p53 at l7p13.1; and (2) a newly defined breast/ovary syndrome which is linked to genetic markers at 17q2l. The California state-mandated Cancer Surveillance Program of Orange County (CSPOC) will be used to identify 500 early onset (<age 50) breast cancer cases and 300 ovarian cancer cases of all ages. The parameters needed to identify families and patients with hereditary breast/ovarian cancer will be estimated by applying segregation analysis to family history data for first- and second-degree relatives. Using these parameters, the odds favoring Mendelian segregation of the breast/ovarian cancer phenotype, and the maximum potential lod score for individual families will be determined. Families with greater than 100:1 odds favoring Mendelian segregation, and with a potential lod score greater than 2.0 will be subjected to more extensive studies, and will be entered into a hereditary cancer registry which is linked to the CSPOC database. Multiple cancer families will also be identifIed from the CSPOC database and entered in the study if they meet ascertainment-adjusted segregation criterion. The p53 gene will be examined for inherited mutations in individual patients and obligate gene carriers from hereditary breast/ovarian cancer families in order to determine the frequency of inherited p53 mutations and to determine the specific p53 cancer-predisposing sequence variation which defines different Li-Fraumeni variants. Forty gene linkage families will be identified and marker typing for l7q2l markers will be undertaken in order to identify families with the breast/ovarian syndrome, and to determine the frequency of the disorder among hereditary families. Genetic-marker development and existing computer software designed for high resolution genetic mapping will be extended to direct the strategies for identifying the 1-2 cM region surrounding the breast/ovarian cancer locus in l7q-linked families. This study will provide the means for identifying a large fraction of the population who are at genetically high risk for breast or ovarian cancer, and for determining the significance of inherited cancer predisposing genes as cancer risk factors in the population. It will help develop therapeutic decisions and cancer prevention measures that meet the specific needs of gene carriers by providing the population and molecular data needed to design clinical management and screening programs. Finally, the study of inherited cancer predisposing-mutations will greatly improve our understanding of cancer etiology and progression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA058860-04S1
Application #
2737338
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Seminara, Daniela
Project Start
1994-02-04
Project End
1998-09-29
Budget Start
1997-01-01
Budget End
1998-09-29
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Irvine
State
CA
Country
United States
Zip Code
92697
Carpenter, Philip M; Ziogas, Argyrios; Markham, Emma M et al. (2018) Laminin 332 expression and prognosis in breast cancer. Hum Pathol 82:289-296
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Muranen, Taru A; Greco, Dario; Blomqvist, Carl et al. (2017) Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med 19:599-603
Hampras, Shalaka S; Sucheston-Campbell, Lara E; Cannioto, Rikki et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget 7:69097-69110
Wyszynski, Asaf; Hong, Chi-Chen; Lam, Kristin et al. (2016) An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet 25:3863-3876
Schmidt, Marjanka K; Hogervorst, Frans; van Hien, Richard et al. (2016) Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 34:2750-60
Zeng, Chenjie (see original citation for additional authors) (2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
Amankwah, Ernest K; Lin, Hui-Yi; Tyrer, Jonathan P et al. (2015) Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol 39:689-97
Mavaddat, Nasim; Pharoah, Paul D P; Michailidou, Kyriaki et al. (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107:

Showing the most recent 10 out of 66 publications